New Approach Methodologies in Biopharmaceutics: Towards a More Humane Drug Development
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 29
Special Issue Editors
2. Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Angamos, Antofagasta 0610, Chile
Interests: bioavailability and bioequivalence; ADMET; QSPR; biopharmaceutics classification system; in vivo-in
2. Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
3. School of Pharmacy, Faculty of Chemistry and Pharmacy, Pontifical Catholic University of Chile, AV. VICUNA MACKENNA 4860, Santiago 7820436, Chile
Interests: biopharmaceutics; dissolution; permeability; pharmacokinetics; modelling
Interests: biopharmaceutics; drug absorption; modeling; oral dosage forms; pulmonary dosage forms; physical pharmacy
Special Issue Information
Dear Colleagues,
Animal testing has been widely used by the pharmaceutical industry at different stages of drug development. In fact, studies in pre-clinical models are key milestones before advancing into first-in-human trials. The 3Rs principles, replacement, reduction, and refinement, have been proposed to conduct more humane animal research. In recent years, the U.S Food and Drug Administration (FDA) has acknowledged their commitment towards reducing animal testing. This initiative relies not only on the ethical concerns of experimentation in animals, but also on the physiological differences between humans and animal models. In this regard, the development of new approach methodologies (NAMs) has the potential of producing more reliable human models than animals. NAMs include, but may not be limited to, advanced computational models, human organoids and organ-on-a-chip systems.
Biopharmaceutics is the branch of pharmaceutical sciences that study the interaction between physicochemical properties of the drug/formulation and the physiological aspects of the route of administration. Hence, biopharmaceutics can be used to guide the rational development of drug products. Accordingly, the development of physiologically relevant NAMs would be highly attractive to screen promising drug candidates, predict drug absorption, select the route of administration, design enabling formulations and/or assess comparative bioavailability (bioequivalence) between drug products. The embracement of such new technologies would be key to advance towards a more humane drug development process.
With this Special Issue, we aim to provide a platform for exchanging research, innovations, and views, from academia, industry and regulators, on the development of (in vitro and in silico) NAMs for biopharmaceutics purposes. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:
- Biorelevant in vitro dissolution;
- In vitro permeability methods;
- Organoids and organ-on-a-chip methods;
- Effect of excipients on drug biorelevant dissolution or permeation;
- Physiologically based biopharmaceutic models;
- Artificial Intelligence-based models;
- Novel devices for biopharmaceutic characterization (e.g., 3D printing).
We look forward to receiving your contributions.
Dr. Miguel Ángel Cabrera-Pérez
Dr. Daniel Hachim
Dr. Mauricio A. García
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biopharmaceutics
- new approach methodologies
- model and simulations
- organoids
- organ-on-a-chip
- biorelevant in vitro dissolution
- In vitro permeability
- effect of excipients
- biopharmaceutic-oriented drug development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
